How to craft responsive clinical trials that are designed for successWithout the right design, right data and right decisions, idealised clinical trial plans cannot be translated into blueprints Share XHow to craft responsive clinical trials that are designed for successhttps://pharmaphorum.com/r-d/how-to-craft-responsive-clinical-trials-that-are-designed-for-success/
Pharma’s reputation problem goes beyond pricing – people don’t know what it stands forMatthew Hare-Scott argues that renewed attacks on the industry from politicians have much to do with pharma losing Share XPharma’s reputation problem goes beyond pricing – people don’t know what it stands forhttps://pharmaphorum.com/views-and-analysis/pharmas-reputation-problem-goes-beyond-pricing-people-dont-know-what-it-stands-for/
AstraZeneca and lung cancer: the pharmaphorum podcastThis episode of the pharmaphorum podcast focuses on lung cancer, with AstraZeneca’s VP, global franchise head, Tagrisso TDR Share XAstraZeneca and lung cancer: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/astrazeneca-and-lung-cancer
Lung cancer’s patient information gap: the pharmaphorum podcastFor episode 13 of the pharmaphorum podcast podcast I went to AstraZeneca’s London base to meet Paul Naish, Share XLung cancer’s patient information gap: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/lung-cancers-patient-information-gap
ASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trialKantar analyst Katie Stockstill discusses the results of phase 3 SOPHIA trial that were presented on the last Share XASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trialhttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/kantar-macrogenics-phase-3-sophia-trial/
ASCO 2019 – Kantar debates results from the KEYNOTE-062 trialThere were a number of debate-worthy outcomes from the KEYNOTE-062 trial that was presented at ASCO 2019 in Share XASCO 2019 – Kantar debates results from the KEYNOTE-062 trialhttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-kantar-debate-results-from-keynote-062-trial/
ASCO 2019 – Kantar reviews results from phase 3 POLO trialLynparza is paving new ground in pancreatic cancer, aiming to establish a maintenance setting and patient segmentation based Share XASCO 2019 – Kantar reviews results from phase 3 POLO trialhttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-kantar-phase-3-polo-trial/
Biotech strategy and nanomedicine: the pharmaphorum podcastFor episode 5 of the pharmaphorum podcast Dominic Tyer met Blueberry Therapeutics’ CEO Dr John Ridden at The Share XBiotech strategy and nanomedicine: the pharmaphorum podcasthttps://pharmaphorum.com/r-d/biotech-strategy-and-nanomedicine/
